Teva CEO Kåre Schultz sees “no dramatic change” in terms of generic price erosion for the Israeli firm in both the US and Europe, as Teva delivered solid first-quarter financial results, including more than $1bn of generic and biosimilar revenues in North America.
Only 24 hours before Teva revealed financial results to the market, Sandoz told investors that on a global basis it...




